Abstract: Cyclooxygenase 2 (COX-2) is an inducible enzyme responsible for the conversion of arachidonic acid into the prostaglandins, PGG2 and PGH2. Expression of this enzyme increases in inflammation. Therefore, the development of probes for imaging COX-2 with positron emission tomography (PET) has gained interest because they could be useful for the study of inflammation in vivo, and for aiding anti-inflammatory drug development targeting COX-2. Nonetheless, effective PET radioligands are still lacking. We synthesized eleven COX-2 inhibitors based on a 2(4-methylsulfonylphenyl)pyrimidine core from which we selected three as prospective PET radioligands based on desirable factors, such as high inhibitory potency for COX-2, very low inhibitory potency for COX-1, moderate lipophilicity, and amenability to labeling with a positron-emitter. These inhibitors, namely 6-methoxy-2-(4-(methylsulfonyl)phenyl-N-(thiophen-2ylmethyl)pyrimidin-4-amine (17), the 6-fluoromethyl analogue (20), and the 6-(2-fluoroethoxy) analogue (27), were labeled in useful yields and with high molar activities by treating the 6-hydroxy analogue (26) F]27 were readily purified with HPLC and formulated for intravenous injection. These methods allow these radioligands to be produced for comparative evaluation as PET radioligands for measuring COX-2 in healthy rhesus monkey and for assessing their abilities to detect inflammation.
Introduction
Cyclooxygenase has two isoforms, COX-1 and COX-2, that exist in endoplasmic reticulum and produce prostaglandins G2 and H2 from arachidonic acid. Prostaglandins are important mediators of symptoms of inflammation, such as fever and pain [1] . COX-1 has been regarded as a widespread constitutive enzyme that is responsible for homeostatic prostaglandin synthesis. By contrast, COX-2 has been regarded as an inducible enzyme whose overexpression is implicated in the progression of many pathological and neurological disorders [2] [3] [4] , including cancers [5] , rheumatoid arthritis [6] , cerebral ischemia [7] , Alzheimer's disease [2] [3] [4] 8] , and Parkinson's disease [2] [3] [4] 9] . Consequently, COX-2 could prove to be useful as a biomarker [1] for the early detection of inflammation in periphery Chart 1. Some features of former candidate COX-2 positron emission tomography (PET) radioligands. Data are from the literature cited in the text, except for clogD values which were computed from 2-dimensional structure with Pallas software (see Experimental). 
Results and Discussion

Target Inhibitor Selection for Radioligand Development
We identified five 2-(4-methylsulfonylphenyl)pyrimidines (17) (18) (19) 22 , and 25) from the report of Orjales et al. [35] that presented: (i) high potency for inhibition of human COX-2 from human whole blood (IC 50 ≤ 5.1 nM); (ii) very low potency for inhibition of the isoform COX-1 from human whole blood (IC 50 > 100 nM); (iii) computed lipophilicity in an acceptable range for a PET radioligand (clogD 2-3, ideally about 2.2); and (iv) at least one site that was expected to be amenable to labeling with either carbon-11 or fluorine-18. In addition to moderate lipophilicity, we sought other properties in these inhibitors that would be consistent with ability to traverse the blood-brain barrier, such as molecular weight of less than 500 Da, computed total polar surface area (tPSA) of less than 90 Å 2 , low hydrogen bond donor number (HBD), less than 9 heteroatoms, pKa less than 9.5, and absence of acidic ionizable groups such as sulfonamido and carboxyl groups [32] (Table 1) . We designed another five previously unknown 2-(4-methylsulfonylphenyl)pyrimidines (20, 21, 27, 29, and 30) as potentially new and potent COX-2 inhibitors with other ostensibly favorable properties for PET radioligand development ( Table 1) . Each of these compounds carried a group that was expected to be readily amenable for labeling with either carbon-11 or fluorine-18 (i.e., in Table 1 the R 1 group with carbon-11 for 21 and with fluorine-18 for 20, 27, and 29; and the R 3 group with carbon-11 for 30). We also prepared two hydroxy compounds with low COX inhibitory potency [35] as possible labeling precursors, namely 24 and 26.
Chemistry
Scheme 1 summarizes the chemistry used to prepare known COX-2 inhibitors, potentially new inhibitors, and precursors for radiolabeling. A key synthesis material, 4,6-dichloro-2-(4(methylsulfonyl) phenyl)pyrimidine (11) , was prepared in five steps, essentially as already described [35] , starting with a Pinner reaction [36] on 4-(methylthio)benzonitrile, followed by amination, cyclization, chlorination, and oxidation. Compound 11 was readily converted into three known inhibitors [35] , namely the two ethers, 4-chloro-6-methoxy-2-(4-(methylsulfonyl)phenyl)pyrimidine (12) and 4-chloro-6-ethoxy-2-(4-(methylsulfonyl)phenyl)pyrimidine (13) , plus the thioether 4-chloro-6-(ethylthio)-2-(4-(methylsulfonyl)phenyl)pyrimidine (14) , each by treatment with the respective alkoxide. The analogous 4-chloro-6-(2-fluoroethoxy) (15) and 4-chloro-6-thiomethyl ethers (16) were prepared similarly in high (80%) and moderate (48%) yield, respectively. Treatment of this set of five ethers with thiophen-2-ylmethanamine under lengthy conditions (120 h) [35] , or with our newly devised and very brief (25 min) microwave method, gave the N-(thiophen-2-ylmethyl)pyrimidin-4-amines 17-21 as some of the known and prospective inhibitor targets.
In two cases, the yields from the non-optimized microwave-method matched (20) or surpassed those from the non-microwave method (21) . Yields of the five N-(thiophen-2-ylmethyl)pyrimidin-4-amines by either method ranged from moderately low (22%) to high (80%). Treatment of 12 with benzylamine instead of thiophen-2-ylmethanamine under either set of reaction conditions gave 33% yield of target inhibitor 22. Treatment of the dichloro compound 11 with benzylamine under the non-microwave conditions gave inhibitor 23 in high yield (76%). The microwave method was not tested for this compound. Likewise, treatment of 11 with thiophen-2ylmethanamine gave ligand 25 in high yield (74%) by either method.
Treatment of 11 with potassium fluoride [37] replaced both chloro groups to give the difluoro analogue 28 in 30% yield. Treatment of 28 with thiophen-2-ylmethanamine under microwave conditions then gave the fluoro compound 29 in 53% yield, a slightly higher yield than obtained under the slower non-microwave conditions (47%).
The 4-chloro compounds 23 and 25 were readily converted with cesium hydroxide under palladium(II)-mediated conditions [38] into the respective 4-hydroxy analogues, 24 and 26, in low but useful yields (20% and 22%, respectively). Treatment of 26 with fluoroiodomethane under basic conditions gave the 4-fluoromethyl compound 27 in 56% yield. Finally, treatment of 25 with iodomethane with sodium hydride in DMF gave the N-methyl derivative 30 in 46% yield. 
COX-1 and COX-2 Inhibition Assays
Species differences in the structures of COXs are well documented, especially between rodent and human [39] . Therefore, the choice of pre-clinical species for evaluation of prospective PET radioligands must be made with care. We aimed to use rhesus monkey if inhibitors from the 2-(4-methylsulfonylphenyl)pyrimidine class showed very similar COX inhibitory potency between rhesus monkey and human. The 2-(4-methylsulfonylphenyl)pyrimidines of interest were tested for COX-1 and COX-2 inhibitory potencies using fresh monkey and human blood (Table 2 ). For compounds whose potencies for inhibiting human COX-1 and COX-2 had already been reported (17-19, 22, 24, 25) [35] , our assay results were in fair agreement for rank order of inhibitory potency, except that we obtained somewhat higher IC50 values for human COX-2 inhibitory potency. None of the tested compounds showed monkey or human COX-1 inhibitory IC50's below 1 nM, in accord with the observations of Orjales et al. [35] for all compounds in this class. These compounds appear to be too bulky for strong binding to the COX-1 isoform.
The thioethyl compound 19 and the hydroxy compound 26 showed much lower inhibitory potency for monkey COX-2 than that reported for human COX-2 [35] . Nevertheless, in several other cases (17, 20-22, 24, 27) inhibitory potencies for the monkey COX enzymes were found to be very close to those for the human enzymes. Therefore, we concluded that monkey could indeed serve as a useful preclinical model for testing candidate PET radioligands for imaging COX-2. 
Species differences in the structures of COXs are well documented, especially between rodent and human [39] . Therefore, the choice of pre-clinical species for evaluation of prospective PET radioligands must be made with care. We aimed to use rhesus monkey if inhibitors from the 2-(4-methylsulfonylphenyl)pyrimidine class showed very similar COX inhibitory potency between rhesus monkey and human. The 2-(4-methylsulfonylphenyl)pyrimidines of interest were tested for COX-1 and COX-2 inhibitory potencies using fresh monkey and human blood ( Table 2 ). For compounds whose potencies for inhibiting human COX-1 and COX-2 had already been reported (17-19, 22, 24, 25) [35] , our assay results were in fair agreement for rank order of inhibitory potency, except that we obtained somewhat higher IC 50 values for human COX-2 inhibitory potency. None of the tested compounds showed monkey or human COX-1 inhibitory IC 50 's below 1 nM, in accord with the observations of Orjales et al. [35] for all compounds in this class. These compounds appear to be too bulky for strong binding to the COX-1 isoform.
The thioethyl compound 19 and the hydroxy compound 26 showed much lower inhibitory potency for monkey COX-2 than that reported for human COX-2 [35] . Nevertheless, in several other cases (17, 20-22, 24, 27) inhibitory potencies for the monkey COX enzymes were found to be very close to those for the human enzymes. Therefore, we concluded that monkey could indeed serve as a useful preclinical model for testing candidate PET radioligands for imaging COX-2. Among the N-(thiophen-2-ylmethyl)pyrimidin-4-amines, monkey and human COX-2 inhibitory potency depended on compound structure in the following manner. Compounds containing an electron-donating group in the R 1 position of the general structure shown in Table 2 , such as OMe (17) , OEt (18) , SEt (19) , OCH2CH2F (20) , SMe (21), or OCH2F (27) , showed high COX-2 inhibitory potencies with IC50's between 1 and 5 nM. Compounds containing relatively small electron withdrawing groups, such as Cl (25) Among the N-(thiophen-2-ylmethyl)pyrimidin-4-amines, monkey and human COX-2 inhibitory potency depended on compound structure in the following manner. Compounds containing an electron-donating group in the R 1 position of the general structure shown in Table 2 , such as OMe (17), OEt (18) , SEt (19), OCH 2 CH 2 F (20), SMe (21), or OCH 2 F (27), showed high COX-2 inhibitory potencies with IC 50 's between 1 and 5 nM. Compounds containing relatively small electron withdrawing groups, such as Cl (25) or F (29) , in the R 1 position also showed quite high COX-2 inhibitory potency (IC 50 , 3-4 nM). N-Methylation of 25 effectively abolished inhibitory potency at human COX-2. Replacement of the 2-thienyl group of 17 with a phenyl group as in 22 resulted in decreased COX-2 inhibitory potency. Compounds 17, 20, and 27 showed the highest inhibitory potencies for COX-2 in both species. The phenols, 24 and 26, which were potentially useful as precursors for radiolabeling, showed low inhibitory potency for COX-2 [35] .
Pharmacological Screening
At 10 µM concentration, inhibitors 17, 18, 27, and 30 showed less than 50% inhibition of radioligand binding at all tested receptors, transporters, and binding sites, except 17 (50, 50.6 and 53.7% inhibition at 5-HT1 B , benzodiazepine (BzP), and DAT (dopamine transporter), respectively), and 27 (50.8% inhibition at BzP). Therefore, this class of COX-2 inhibitor was generally devoid of very high binding affinity at any of the tested off-target sites, as is desirable for an effective PET radioligand.
Selection of Candidates for Radiolabeling
Inhibitors 17, 20, and 27 were selected from the prepared set (Table 2 ) for radiolabeling because they presented the highest inhibitory potencies for human and monkey COX-2, very low inhibitory potency for human and monkey COX-1, computed lipophilicities in a range generally acceptable for PET radioligands, and readily accessible positions for labeling with 11 C (17) or 18 F (20 and 27). decreased COX-2 inhibitory potency. Compounds 17, 20, and 27 showed the highest inhibitory potencies for COX-2 in both species. The phenols, 24 and 26, which were potentially useful as precursors for radiolabeling, showed low inhibitory potency for COX-2 [35] .
Pharmacological Screening
At 10 μM concentration, inhibitors 17, 18, 27, and 30 showed less than 50% inhibition of radioligand binding at all tested receptors, transporters, and binding sites, except 17 (50, 50.6 and 53.7% inhibition at 5-HT1B, benzodiazepine (BzP), and DAT (dopamine transporter), respectively), and 27 (50.8% inhibition at BzP). Therefore, this class of COX-2 inhibitor was generally devoid of very high binding affinity at any of the tested off-target sites, as is desirable for an effective PET radioligand.
Selection of Candidates for Radiolabeling
Inhibitors 17, 20, and 27 were selected from the prepared set (Table 2 ) for radiolabeling because they presented the highest inhibitory potencies for human and monkey COX-2, very low inhibitory potency for human and monkey COX-1, computed lipophilicities in a range generally acceptable for PET radioligands, and readily accessible positions for labeling with 11 C (17) or 18 F (20 and 27). The radiochemical purities of all three radioligands exceeded 99% (Figure 1 ). Formulated radioligands were free of appreciable amounts of labeling precursor (26) or derived impurities (Figure 1 ). Each formulated radioligand was radiochemically stable for more than 1 h as measured by HPLC.
Calculated and Measured LogD for Prepared Radioligands
The measured lipophilicity values (logD's) for Table 3 ). The measured value for [ 18 F]20 was almost the same as the computed value. All the measured values were within the logD range (2-4) observed for many effective PET radioligands for imaging proteins in brain [44] , but rather higher than might be considered ideal. [35] . SE of values were <15%. d n = 1. e n = 2.
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OCH2F 2-Thi H >1000 >1000 2.26 ± 0.45 2.26 ± 0.63 29 F 2-Thi H 2.5 d 30 Cl 2-Thi Me > 10 8 d >1000 a Data are for mean ± SD from triplicate measurements, unless otherwise stated. b 2-Thi = 2-thienyl c Data from reference
Radiochemistry
Three radioligands, The radiochemical purities of all three radioligands exceeded 99% (Figure 1 ). Formulated radioligands were free of appreciable amounts of labeling precursor (26) or derived impurities (Figure 1 ). Each formulated radioligand was radiochemically stable for more than 1 h as measured by HPLC.
Calculated and Measured LogD for Prepared Radioligands
The measured lipophilicity values (logD's) for [ 11 C]17 and [d2-18 F]27 were higher than the computed values by 0.94 and 0.98, respectively ( Table 3 ). The measured value for [ 18 F]20 was almost the same as the computed value. All the measured values were within the logD range (2-4) observed for many effective PET radioligands for imaging proteins in brain [44] , but rather higher than might be considered ideal. 
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Solvents (analytical grade) and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless stated otherwise. The products were isolated with flash chromatography on a 
Experimental
General
Solvents (analytical grade) and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless stated otherwise. The products were isolated with flash chromatography on a CombiFlash Rf+ system (Teledyne ISCO; Lincoln NE) equipped with a silica gel cartridge (12 g, RediSep ® Rf; Isco: Lincoln, NE, USA) using hexane and EtOAc as mobile phase (general method A). If necessary to achieve purity exceeding 95%, COX-2 inhibitors were subjected to reversed phase HPLC (Beckman Coulter, Fullerton, CA, USA) on an XBridge C18 column (19 × 150 mm, 10 µm; Waters; Milford, MA, USA) eluted at 6 mL/min with a gradient mobile phase composed of aq. ammonium hydroxide (0.25 mM) (A) and acetonitrile (B) (general method B), with eluate monitored for absorbance at 254 nm. Melting points were determined on an SMP20 apparatus (Stuart; Staffordshire, UK). 1 H (400.13 MHz), 13 The chemical purities of all prepared inhibitors were shown to be >95% with analytical reversed phase HPLC on a Luna C18 (2) column (250 × 4.6 mm, 10 µm; Phenomenex; Torrance, CA, USA) eluted isocratically with ammonium formate (10 mM)−acetonitrile (50:50) at 2 mL/min (general method C). Eluate was monitored for absorbance at 254 nm (see Supporting Information).
cLogD values and pKa values were computed with Pallas for Windows software version 3.8 in default option (CompuDrug International; Bal Harbor, FL, USA). tPSA's were estimated with ChemDraw version 10 (CambridgeSoft, Cambridge, MA, USA).
Synthesis of Target Compounds and Precursors for Radiolabeling
Ether Derivatives of 4,6-Dichloro-2-(4-methylsulfonylphenyl)pyrimidine
4,6-Dichloro-2-(4-methylsulfonylphenyl)pyrimidine (11) was prepared in five steps from 4-(methylthio)benzonitrile and converted into the ethers 4-chloro-6-methoxy-2-(4-(methylsulfonyl) phenyl)pyrimidine (12) and 4-chloro-6-ethoxy-2-(4-(methylsulfonyl)phenyl)pyrimidine (13) , and the thioether 4-chloro-6-(ethylthio)-2-(4(methylsulfonyl)phenyl)pyrimidine (14) , all according to literature methods [35] .
4-Chloro-6-(2-fluoroethoxy)-2-(4-(methylsulfonyl)phenyl)pyrimidine (15).
Compound 11 (200 mg, 0.659 mmol), sodium hydride (25 mg, 1.04 mmol) and 2-fluoroethanol (41.5 µL, 0.715 mmol) in THF (1.5 mL) was added to an oven-dried pressure tube and kept at RT (room temperature) for 3 h. The solvent was evaporated off under reduced pressure. The residue was quenched with water (5 mL) and extracted with EtOAc (5 mL × 3). The organic layers were combined, washed with brine-water (1:1 v/v: 15 mL × 2), dried (MgSO 4 ) and concentrated under reduced pressure. The residue was purified with flash chromatography (general method A) to give crude product (176 mg, 80%). This product was further purified with reversed phase HPLC (general method B) using a gradient mobile phase composed of aq. ammonium hydroxide (0.25 mM) (C) and acetonitrile (D), starting at 20% D and rising linearly to 95% D at 60 min to give 15 as an off-white solid; mp: 158.5-160.1 • C; 1 4-Chloro-6-(methylthio)-2-(4-(methylsulfonyl)phenyl)pyrimidine) (16) . Sodium methanethiolate (36.4 mg, 0.519 mmol) and THF (6.0 mL) were loaded into a Schlenk tube (25-mL volume) under argon. A solution of 11 (166 mg, 0.547 mmol) in THF (1.0 mL) was then added dropwise. The Schlenk tube was sealed and heated at 50 • C for 3 h. The mixture was then quenched with water (10 mL), extracted with EtOAc (10 mL × 3) and washed with aq. NaHCO 3 (0.1 M; 10 mL). The product was dried (MgSO 4 
Conversion of 4-Halo-2-(4-(methylsulfonyl)phenyl)-pyrimidine Derivatives into 4-Alkylamino Derivatives
General procedure A (non-microwave method) (GP1). This method was based on that in reference [35] , as follows. A mixture of the appropriate 4-halo-2-(4-(methylsulfonyl)phenyl)-pyrimidine derivative (1 mmol) with Et3N (2-4 mmol) and the corresponding amine (2-4 mmol) in MeCN (7 mL) was stirred at RT for 5 d. Solvent was then removed under vacuum and the resulting residue purified with flash chromatography (general method A; 20-80% ethyl acetate in hexane). If needed, compounds were further purified to >95% purity with HPLC.
General procedure B (fast microwave method) (GP2). The appropriate 4-halo-2-(4-(methylsulfonyl) phenyl)-pyrimidine (1 mmol), and corresponding amine (0.2-1 mmol), Cs 2 CO 3 (30 mmol %), and DMF (1.00 mL) were added to a 10-mL microwave vial (Discover; CEM, NC) containing a stirrer bar. The sealed vial was irradiated (100 W) at 160 • C for 25 min. The vial contents were extracted with water (10 mL) and EtOAc (10 mL × 3), and then washed with aq. NaHCO 3 (0.1 M; 10 mL). The combined organic layers were dried (silica gel) and the product isolated with flash chromatography (general method A; 20-80% ethyl acetate in hexane). If needed, compounds were further purified to >95% purity with reversed phase HPLC (general method B) on an XBridge C18 column using a gradient mobile phase composed of aq. ammonium hydroxide (0.25 mM) (C) and acetonitrile (D), starting at 20% D rising linearly to 95% D at 60 min.
6-Methoxy-2-(4-(methylsulfonyl)phenyl)-N-(thiophen-2-ylmethyl)pyrimidin-4-amine (17). GP2 on 12 (0.209 mmol; 62.6 mg) and thiophen-2-ylmethanamine gave 17 as an off-white solid (22 mg; 29%); mp 139.0-141.0 • C; lit. mp 120.0-124.1 • C [35] ; 1 H and 13 C-NMR data matched those in the literature [35] ; HPLC (general method C; t R = 11.5 min; purity 99.4%). From GP1 (55%).
6-Ethoxy-2-(4-(methylsulfonyl)phenyl)-N-(thiophen-2-ylmethyl)pyrimidin-4-amine (18). GP1 on 13 and thiophen-2-ylmethanamine gave 18 as a white solid (68.3 mg; 64%); mp 169.2-170.4 • C; lit. mp 160-162.2 • C [35] ; 1 H and 13 C-NMR data matched those in the literature [35] ; HPLC (general method C; t R = 12.8 min, purity 99.4%). From GP2 (22%).
6-Thioethyl-2-(4-(methylsulfonyl)phenyl)-N-(thiophen-2-ylmethyl)pyrimidin-4-amine (19) . GP1 on 14 and thiophen-2-ylmethanamine gave 19 as a white solid (111 mg, 80%); mp: 160.0-162.1 • C; lit.mp 152.0-153.9 • C [35] ; 1 H and 13 C-NMR data matched those in the literature [35] ; HPLC (general method C; t R = 4.5 min; purity 99.3%). From GP2 (55%). 169.10, 161.23, 161.11, 143.12, 141.08, 129.12, 127.26, 126.94, 125.87, 125.31, 44.56, 40.36 General procedure for conversion of 4-chloropyrimidine derivatives into 4-hydroxypyrimidine derivatives (GP3). The appropriate 4-chloropyrimidine derivative (1 mmol), Pd 2 dba 3 (2 mol%), Bippyphos (8 mol%), CsOH·H 2 O (3 mmol), 1,4-dioxane (2 mL), and a stirrer bar were loaded into an oven-dried pressure-cap vial. The vial was sealed under argon. The contents were stirred vigorously at 100 • C for 20 h and then allowed to cool. The solution was made acidic (pH 3) with hydrochloric acid (2 M), diluted with water (5 mL), extracted with EtOAc (5 mL × 3), and dried (MgSO 4 ). Product was then isolated with HPLC. 
Radiochemistry
Radiochemistry Materials and Methods
Radioactivity from carbon-11 or fluorine-18 was measured with a calibrated dose calibrator (Atomlab 300, Biodex Medical Systems, Shirley, NY, USA) or an automatic γ-counter (Wizard 3", 1480; PerkinElmer; Waltham, MA, USA). Radioactivity measurements were corrected for physical decay. Radiochemistry was executed in lead-shielded hot-cells for personal protection from radiation. Radioligands were separated with reversed phase HPLC (Beckman Coulter, Fullerton, CA, USA) on a Luna (C-18/2) column (10 × 250 mm, 10 µm; Phenomenex; Torrance, CA, USA). Radioligands were identified and measured for radiochemical purity with reversed phase HPLC (Beckman Coulter, Fullerton, CA, USA) on a Luna C18 (2) column (4.6 × 250 mm, 10 µm). All HPLC column eluates were monitored for radioactivity and absorbance at 254 nm. Absorbance responses for analytical HPLC systems were calibrated for mass of injectates to enable molar activities [47] to be measured. The phenol precursor 26 (1.01 mg, 2 µmol) was dissolved in DMF (80 µL) at 7 min before the end of radionuclide production. The solution was sonicated and then TBAH in methanol (1 M, 3.0 µL) was added. This solution was loaded into the loop (constructed of stainless steel tubing) of an AutoLoop apparatus (Bioscan; Washington, DC, USA). 27 were measured by a method that we have described previously [49] . The radioactivity contents in the n-octanol and sodium phosphate buffer (0.1 M; pH 7.4) phases were determined with a γ-counter.
Conclusions
Three COX-2 inhibitors, 17, 20, and 27, were identified from the 2-(4-methylsulfonylphenyl)-pyrimidine class as having promising physiochemical and pharmacological properties for development as PET radioligands for imaging COX-2 in monkey and human in vivo. Methods were established for satisfactorily labeling these ligands with positron-emitters for comparative PET imaging in monkey in vivo, including a neuroinflammation model [50] . These results will be published in detail elsewhere. 
